Zikherman, Julie
- University of California, San Francisco · Internal Medicine (NIH department code)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #10,329
- R01 Holder
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2010 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Internal Medicine
NIH Funding · FY2023
Linked Award Amount
$991.5K
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#10,329
By linked amount among FY2023 PIs
Earliest Year Loaded
2010
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Zikherman, Julie as a PI. Multi-PI records show the full award amount for context.
- 5R01AI165706-02R01Contact PIRegulation of CD4 T cell tolerance by the NR4A family of nuclear receptorsUniversity of California, San Francisco · Internal Medicine (NIH department code)$587.7Kaward amount
- 5R01AI148487-04R01Contact PINuclear Receptors in B Cell Tolerance and Humoral Immune ResponsesUniversity of California, San Francisco · Internal Medicine (NIH department code)$403.8Kaward amount
Award organization
Organizations that administered FY2023 awards listing Zikherman, Julie as a PI.
FY2023 award administered by University of California, San Francisco (CA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2010First NIH AwardUniversity of California, San Francisco
- 2014$500K Cumulative Funding
- 2014R01 Grant Holder
- 2017$1M Cumulative Funding
- 2020$2M Cumulative Funding
- 2022Entered Top 50% NationallyRanked #9682